HR+ Breast Cancer: Treatment Advances and Highlights from ASCO 2025 - Episode 1
Panelists discuss how they will review the latest updates in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer, focusing on oral selective estrogen receptor degraders (SERDs), targeted therapies, and antibody-drug conjugates presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Introduction and Panel Overview
This OncLive Peer Exchange® from ASCO 2025 in Chicago focuses on hormone receptor–positive breast cancer treatment advances and highlights from the conference. The panel brings together leading breast oncology experts from major academic institutions, including the University of Chicago, UCLA, University of California San Diego, Washington University, and City of Hope. The discussion centers on the latest developments in hormone receptor–positive, HER2-negative, and HER2-low metastatic breast cancer treatment.
The experts introduce the session’s comprehensive agenda covering oral SERDs, targeted therapies, and antibody-drug conjugates that are transforming the breast cancer treatment landscape. Key topics include reviewing critical trial data presented at ASCO 2025, particularly the SERENA-6 trial for capivasertib, and exploring how these emerging therapies are being integrated into clinical practice. The panel aims to provide practical insights for oncologists treating patients with hormone receptor–positive metastatic breast cancer.
This peer exchange represents a timely discussion of cutting-edge developments in breast cancer treatment, offering evidence-based perspectives on the rapidly evolving therapeutic options available to patients with hormone receptor–positive disease. The session promises to deliver actionable insights for improving patient outcomes in this specific breast cancer subtype.